Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $19.00 Consensus PT from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $19.00.

Several equities analysts have issued reports on FULC shares. Bank of America raised their price objective on Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a report on Tuesday, December 9th. Leerink Partners set a $20.00 price target on Fulcrum Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Cantor Fitzgerald lifted their price target on Fulcrum Therapeutics from $15.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Royal Bank Of Canada boosted their price objective on Fulcrum Therapeutics from $7.00 to $10.00 and gave the company a “sector perform” rating in a research note on Monday, December 8th. Finally, The Goldman Sachs Group restated a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday, December 8th.

Insider Buying and Selling at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the transaction, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total transaction of $165,450.00. Following the completion of the sale, the director directly owned 484,864 shares of the company’s stock, valued at $5,348,049.92. The trade was a 3.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP purchased a new position in Fulcrum Therapeutics in the 3rd quarter valued at $35,000. Farther Finance Advisors LLC boosted its holdings in shares of Fulcrum Therapeutics by 108.3% in the third quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after acquiring an additional 9,092 shares in the last quarter. Assetmark Inc. acquired a new position in shares of Fulcrum Therapeutics during the third quarter worth about $88,000. Finally, Jump Financial LLC purchased a new position in Fulcrum Therapeutics during the first quarter worth about $30,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Trading Up 3.5%

FULC stock opened at $11.99 on Thursday. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $15.74. The company’s 50 day moving average is $10.44 and its two-hundred day moving average is $8.53. The stock has a market cap of $648.90 million, a P/E ratio of -10.16 and a beta of 3.17.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, equities research analysts predict that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small?molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.